Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma.
Aged
Aged, 80 and over
Cohort Studies
Cyclin D1
/ genetics
Female
Gene Rearrangement
/ genetics
Histone-Lysine N-Methyltransferase
/ genetics
Humans
Immunohistochemistry
/ methods
Male
Middle Aged
Multiple Myeloma
/ genetics
Proto-Oncogene Proteins c-maf
/ genetics
Repressor Proteins
/ genetics
Sensitivity and Specificity
FFPE tissue sections
gene rearrangements
immunohistochemistry
multiple myeloma
tissue fluorescence in situ hybridization
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
06
02
2019
revised:
01
06
2019
accepted:
17
06
2019
pubmed:
21
6
2019
medline:
14
8
2019
entrez:
21
6
2019
Statut:
ppublish
Résumé
The t(11;14)/CCND1-IGH, t(4;14)/NSD2(MMSET)-IGH, and t(14;16)/IGH-MAF gene rearrangements detected by fluorescence in situ hybridization (FISH) are used for risk stratification in patients with multiple myeloma (MM). Compared with conventional FISH techniques using fresh cells, immunohistochemistry (IHC) is much more cost- and time-efficient, and can be readily applied to routinely prepared formalin-fixed, paraffin-embedded (FFPE) materials. In this study, we performed tissue FISH and IHC employing FFPE specimens, and examined the usefulness of IHC as a tool for detecting CCND1, NSD2, and MAF gene rearrangements. CD138 signals were used to identify plasma cells in tissue FISH and IHC analyses. With cohort 1 (n = 70), we performed tissue FISH and subsequently IHC, and determined IHC cut-off points. In this cohort, the sensitivity and specificity for the 3 molecules were ≥.90 and ≥.96, respectively. With cohort 2, using MM cases with an unknown gene status (n = 120), we performed IHC, and the gene status was estimated using the cut-off points determined with cohort 1. The subsequent FISH analysis showed that the sensitivity and specificity for the 3 molecules were ≥.92 and ≥.98, respectively. CCND1, NSD2, and MAF gene rearrangements were estimated accurately by IHC, suggesting that conventional FISH assays can be replaced by IHC.
Identifiants
pubmed: 31218784
doi: 10.1111/cas.14109
pmc: PMC6676137
doi:
Substances chimiques
CCND1 protein, human
0
MAF protein, human
0
Proto-Oncogene Proteins c-maf
0
Repressor Proteins
0
Cyclin D1
136601-57-5
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
NSD2 protein, human
EC 2.1.1.43
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2600-2606Subventions
Organisme : National Cancer Center Research and Development Fund
ID : 26-A-4
Organisme : Ministry of Education, Culture, Sports, Science, and Technology
ID : 15K08351
Organisme : Ministry of Education, Culture, Sports, Science, and Technology
ID : 16K07179
Organisme : Ministry of Education, Culture, Sports, Science, and Technology
ID : 16K09855
Organisme : Japan Agency for Medical Research and Development
ID : 15ck0106077h0002
Informations de copyright
© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Blood. 2005 Oct 15;106(8):2837-40
pubmed: 15976175
Genes Chromosomes Cancer. 2016 Sep;55(9):710-8
pubmed: 27152944
J Clin Pathol. 2013 Jan;66(1):54-7
pubmed: 23038690
Blood. 2007 Apr 15;109(8):3489-95
pubmed: 17209057
Cancer Discov. 2016 Oct;6(10):1106-1117
pubmed: 27520294
J Clin Pathol. 2005 Dec;58(12):1336-8
pubmed: 16311361
Cancer Sci. 2019 Aug;110(8):2600-2606
pubmed: 31218784
Virchows Arch. 2016 Nov;469(5):575-580
pubmed: 27600807
Leukemia. 2007 Jul;21(7):1572-4
pubmed: 17392817
Endocrinology. 2004 Dec;145(12):5439-47
pubmed: 15331580
Mol Cell Biol. 2012 Aug;32(15):3121-31
pubmed: 22645312
Hum Pathol. 2011 Sep;42(9):1297-304
pubmed: 21396678
Nat Rev Cancer. 2012 Apr 12;12(5):335-48
pubmed: 22495321
Br J Haematol. 2006 Nov;135(4):486-91
pubmed: 16995883
Blood Cancer J. 2015 Feb 27;5:e285
pubmed: 25723856
Haematologica. 2017 Mar;102(3):593-599
pubmed: 27789676
Mayo Clin Proc. 2013 Apr;88(4):360-76
pubmed: 23541011
J Immunol. 2011 Oct 1;187(7):3721-9
pubmed: 21876034
J Clin Oncol. 2010 Oct 20;28(30):4630-4
pubmed: 20644101
J Clin Invest. 2012 Oct;122(10):3456-63
pubmed: 23023717
Blood. 2005 Jul 1;106(1):353-5
pubmed: 15761022
Leukemia. 2003 Dec;17(12):2257-317
pubmed: 14671650
Blood. 2003 Jun 1;101(11):4569-75
pubmed: 12576322
Int J Hematol. 2013 Mar;97(3):313-23
pubmed: 23456262
Leukemia. 2009 Dec;23(12):2210-21
pubmed: 19798094
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
Blood. 2011 Feb 10;117(6):2009-11
pubmed: 20962323
APMIS. 2014 Mar;122(3):183-91
pubmed: 23758159